Clinical data shows Eli Lilly's tirzepatide causes significant lean muscle loss compared to semaglutide. This creates a massive secondary market for 'muscle-sparing' supplements and protocols for the millions on GLP-1s.
Build the 'Ozempic Support Stack'—a high-margin bundle of Creatine, HMB, and Leucine-heavy whey. MVP: White-label via Supliful, launch on TikTok Shop with a 30% affiliate commission for 'Health-Tok' creators. Target the 15-20% muscle loss reported in trials. Mitigate the risk of Big Pharma bundling their own inhibitors by building a community-led 'lifestyle' brand that feels less clinical and more aspirational.
Every GLP-1 user is a high-intent lead for muscle preservation to avoid the 'gaunt' look and metabolic slowdown of sarcopenia.
First-10-customer context captured by Scanner for this opportunity.
Medical Directors and owners of private medical weight loss and longevity clinics in high-income US metropolitan areas like Miami and Los Angeles.
Primary observations behind the opportunity thesis.
Clinical data shows Eli Lilly's tirzepatide causes significant lean muscle loss compared to semaglutide. This creates a massive secondary market for 'muscle-sparing' supplements and protocols for the millions on GLP-1s.
Open signalReceipts, citations, and captured media assets tied to this opportunity.
Clinical data shows Eli Lilly's tirzepatide causes significant lean muscle loss compared to semaglutide. This creates a massive secondary market for 'muscle-sparing' supplements and protocols for the millions on GLP-1s.
Open sourcehttps://endpoints.news/lillys-tirzepatide-sheds-lean-muscle-harder-than-novos-semaglutide-study-suggests/
Open sourceRelevant companies, patterns, industries, and technologies connected to this opportunity.
Country and region facets attached to the opportunity.
Accepted and candidate claims attached to this opportunity.
Build the 'Ozempic Support Stack'—a high-margin bundle of Creatine, HMB, and Leucine-heavy whey. MVP: White-label via Supliful, launch on TikTok Shop with a 30% affiliate commission for 'Health-Tok' creators. Target the 15-20% muscle loss reported in trials. Mitigate the risk of Big Pharma bundling their own inhibitors by building a community-led 'lifestyle' brand that feels less clinical and more aspirational.
Every GLP-1 user is a high-intent lead for muscle preservation to avoid the 'gaunt' look and metabolic slowdown of sarcopenia.
The 'Skinny-Fat' epidemic is a multi-billion dollar problem. Muscle preservation is the new weight loss.
Novo and Lilly will eventually bundle myostatin inhibitors, potentially killing the third-party supplement market.